NBE-Therapeutics is a Swiss Biotechnology company developing antibody-based therapeutics. It is the main focus of NBE-Therapeutics to develop antibody drug conjugates (ADCs) for targeted cancer therapy. For this NBE-Therapeutics has developed proprietary therapeutic antibody discovery and antibody-drug conjugation technologies allowing the development of superior, “next-generation” ADCs.
Novasep provides unique services for the development and cGMP manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody. With a recent €10M investment in a fully integrated ADC facility, Novasep has reinforced its current ADC offering with full bio-conjugation services to meet increasing market demand.
European leader in analytical sciences – Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products. The company holds a unique position on the market thanks to having all its laboratories on one site, 170 highly qualified professionals and more than 35 years’ expertise at the forefront of analytical sciences.
Sartorius-Stedim Biotech is a key supplier of Bioprocessing technologies and Biomanufacturing related services.
Benefit from the most comprehensive bioprocess and single-use technology portfolio coupled with our process engineering expertise, ensuring a robust process development and manufacturing approach… Read more
SCIEX enables drug discovery and development for biologics and small molecule drugs. From identification through peptide mapping and sequence variance analysis ― our advanced LC/MS, LC/MS/MS and CE solutions reduce complexity across the entire process. SCIEX strives to exceed expectations and empower customers to find accurate answers.
BrightGene is a R&D driving pharmaceutical company focus on niche specialty generics and intermediates, with high tech barrier, such as multi-chiral and fermentation
Our manufacturing sites have been approved by FDA EDQM PMDA KFDA and CFDA.
We have full pipeline in ADC cytotoxic payloads, its starting material, and linkers: Read More
At Levena BioPharma, we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND. Our ADC platform encompasses: ADC screening tools; bioactive molecules (toxins) for research and in cGMP grade; optimized linker-toxins; conjugation services; ADC toxicity screening; and ADC optimization & processing.
Morphotek® (www.morphotek.com) is a biotechnology company focused on the development of antibody-based therapies. In oncology, we are developing biological therapies that target underlying disease pathways and can overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies… Read More
Minakem is a technology driven outsourcing partner dedicated to developing and manufacturing fine chemicals, advanced intermediates, APIs and HPAPIs including ADC toxins. A dedicated site having more than 40 years’ experience in high potent compounds, with state-of-the-art containment systems and capability to handle broad range of chemistry from grams to kilos scale, including preparative-HPLC, makes Minakem a partner of choice in HPAPI and ADC toxins development and supply across the full product life cycle.